Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study.

Saved in:
Bibliographic Details
Title: Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study.
Authors: Pinato DJ; Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom.; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy., D'Alessio A; Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom.; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy., Fulgenzi CAM; Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom., Schlaak AE; Department of Internal Medicine, University Hospital Freiburg, Freiburg, Germany., Celsa C; Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom.; Section of Gastroenterology and Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy., Killmer S; Department of Internal Medicine, University Hospital Freiburg, Freiburg, Germany., Blanco JM; Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, St Mary's Hospital Campus, London, United Kingdom., Ward C; Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom., Stikas CV; Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom., Openshaw MR; Institute of Cancer and Genomics Sciences, University of Birmingham, Birmingham, United Kingdom., Acuti N; Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom., Nteliopoulos G; Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom., Balcells C; Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom., Keun HC; Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom., Goldin RD; Centre for Pathology, Imperial College London, Charing Cross Hospital, London, United Kingdom., Ross PJ; Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.; King's College Hospital NHS Foundation Trust, London, United Kingdom., Cortellini A; Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom.; Division of Medical Oncology, Policlinico Universitario Campus Bio-Medico, Rome, Italy., Thomas R; Interventional Radiology, Imperial College NHS Trust, Hammersmith Hospital, London, United Kingdom., Young AM; Department of Medical Oncology, St Georges University Hospitals, NHS Foundation Trust, St George's University Hospitals NHS Foundation Trust, London, United Kingdom., Danckert N; Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, St Mary's Hospital Campus, London, United Kingdom., Tait P; Interventional Radiology, Imperial College NHS Trust, Hammersmith Hospital, London, United Kingdom., Marchesi JR; Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, St Mary's Hospital Campus, London, United Kingdom., Bengsch B; Department of Internal Medicine, University Hospital Freiburg, Freiburg, Germany.; Signalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany, partner site Freiburg., Sharma R; Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Jun 03; Vol. 30 (11), pp. 2433-2443.
Publication Type: Journal Article; Clinical Trial, Phase I; Multicenter Study
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-24-0177